TransMedics Group, Inc. revenue by segment TMDX

TransMedics Group, Inc. splits its revenue into 6 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $372.4 million, 62% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 28, 2019
Revenue
668
605
442
242
93
30
26
26
Product
407
+25.2%
share 60.9%
372
+36.0%
share 61.5%
274
+55.5%
share 62.0%
176
+122.2%
share 72.9%
79
share 84.8%
—
—
—
Services
261
+26.7%
share 39.1%
233
+39.0%
share 38.5%
168
+155.8%
share 38.0%
66
+360.8%
share 27.1%
14
+2251.2%
share 15.2%
1
share 2.0%
—
—
Ocs Heart Product
—
—
—
—
—
18
+24.6%
share 58.4%
14
share 55.4%
—
Ocs Lung Product
—
—
—
—
—
11
+72.2%
share 35.2%
6
share 24.2%
—
Service Unrelated To OCS Transplant
4
+4.7%
share 0.7%
4
-6.8%
share 0.7%
4
-10.2%
share 1.0%
5
share 2.0%
—
—
—
—
Ocs Liver Product
—
—
—
—
—
2
-63.5%
share 6.3%
5
share 20.5%
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
TMDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
MA
Headquarters
Andover, MA
SEC filer status
Large accelerated filer
SEC CIK
1756262

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.